Match!

Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries

Published on Sep 1, 2017in Value in Health5.037
· DOI :10.1016/j.jval.2017.03.011
Wija Oortwijn11
Estimated H-index: 11
(Ecorys),
Domino Determann1
Estimated H-index: 1
(Ecorys)
+ 2 AuthorsJeroen van der Tuin2
Estimated H-index: 2
(Ecorys)
Abstract
Abstract Objectives To assess the level of comprehensiveness of health technology assessment (HTA) practices around the globe and to formulate recommendations for enhancing legitimacy and fairness of related decision-making processes. Methods To identify best practices, we developed an evaluation framework consisting of 13 criteria on the basis of the INTEGRATE-HTA model (integrative perspective on assessing health technologies) and the Accountability for Reasonableness framework (deliberative appraisal process). We examined different HTA systems in middle-income countries (Argentina, Brazil, and Thailand) and high-income countries (Australia, Canada, England, France, Germany, Scotland, and South Korea). For this purpose, desk research and structured interviews with relevant key stakeholders (N = 32) in the selected countries were conducted. Results HTA systems in Canada, England, and Scotland appear relatively well aligned with our framework, followed by Australia, Germany, and France. Argentina and South Korea are at an early stage, whereas Brazil and Thailand are at an intermediate level. Both desk research and interviews revealed that scoping is often not part of the HTA process. In contrast, providing evidence reports for assessment is well established. Indirect and unintended outcomes are increasingly considered, but there is room for improvement. Monitoring and evaluation of the HTA process is not well established across countries. Finally, adopting transparent and robust processes, including stakeholder consultation, takes time. Conclusions This study presents a framework for assessing the level of comprehensiveness of the HTA process in a country. On the basis of applying the framework, we formulate recommendations on how the HTA community can move toward a more integrated decision-making process using HTA.
  • References (21)
  • Citations (8)
📖 Papers frequently viewed together
34 Citations
4 Citations
9 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References21
Newest
#1Sarah BerglasH-Index: 1
#2Lauren Jutai (LSE: London School of Economics and Political Science)H-Index: 1
Last. Laura WeeksH-Index: 1
view all 4 authors...
Plain language summary In Canada, the CADTH Common Drug Review helps ensure that scarce health care resources are used to fund the most effective drugs. Clinicians, researchers, payers, and patients all have important, but potentially different, ideas on what should be considered, to determine a drug’s value. Since 2010, CADTH has invited patient groups to contribute their perspectives to the Common Drug Review. We explored whether, and how, insights offered by patient groups are integrated into...
21 CitationsSource
#1Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 39
#2Wija OortwijnH-Index: 11
Last. Jeroen van der TuinH-Index: 2
view all 8 authors...
Each patient in the European Union has a right of access to care. National governments face the challenge to balance resources against healthcare demand to ensure that populations enjoy equitable access to effective, affordable and sustainable healthcare. This study describes the main challenges with regard to access to affordable medicines, including Research & Development, pricing and reimbursement of medicines and the influence of the economic crisis. Potential policy options to tackle these ...
2 Citations
#1Maarten Jansen (Radboud University Nijmegen)H-Index: 5
#2Jan-Kees Helderman (Radboud University Nijmegen)H-Index: 9
Last. Rob Baltussen (Radboud University Nijmegen)H-Index: 40
view all 4 authors...
Embedding health technology assessment (HTA) in a fair process has great potential to capture societal values relevant to public reimbursement decisions on health technologies. However, the development of such processes for priority setting has largely been theoretical. In this paper, we provide further practical lead ways on how these processes can be implemented. We first present the misconception about the relation between facts and values that is since long misleading the conduct of HTA and ...
7 CitationsSource
#1Philip WahlsterH-Index: 11
#2Louise BreretonH-Index: 12
Last. Ansgar GerhardusH-Index: 12
view all 16 authors...
Challenges in assessments of health technologies In recent years there have been major advances in the development of health technology assessment (HTA). However, HTA still has certain limitations when assessing technologies which are complex, i.e. consist of several interacting components, target different groups or organizational levels, have multiple and variable outcomes, and/or permit a certain degree of flexibility or tailoring (Craig et al., 2008), fi are context-dependent - current HTA us...
15 Citations
#1Louise BreretonH-Index: 12
#2Philip WahlsterH-Index: 11
Last. Elizabeth GoyderH-Index: 27
view all 27 authors...
AUTHORS: Louise Brereton, Philip Wahlster, Kristin Bakke Lysdahl, Kati Mozygemba, Jake Burns, James B. Chilcott, Sue Ward, Jan Benedikt Bronneke, Marcia Tummers, Ralph van Hoorn, Lisa Pfadenhauer, Stephanie Polus, Christine Ingleton, Clare Gardiner, Gert Jan van der Wilt, Ansgar Gerhardus, Anke Rohwer, Eva Rehfuess, Wija Oortwijn, Pietro Refolo, Dario Sacchini, Wojciech Leppert, Aurelija Blazeviciene, Antonio Gioacchino Spagnolo, Louise Preston, Joe Clark, Elizabeth Goyder on behalf of the INTEG...
12 Citations
#1Heather McDonaldH-Index: 8
#2Cathy CharlesH-Index: 31
Last. Amiram Gafni (McMaster University)H-Index: 74
view all 4 authors...
The pan-Canadian Oncology Drug Review (pCODR) makes recommendations to Canada’s provinces and territories (except Quebec) to guide their cancer drug funding decisions. The objective of this paper is to explore, using an economic perspective and the pCODR as an example, the challenges associated with striving to simultaneously achieve the goals of maximizing health benefits with available resources and improving access to a more consistent standard of care across Canada. The first challenge conce...
4 CitationsSource
#1Georges Adunlin (FAMU: Florida A&M University)H-Index: 7
#2Vakaramoko Diaby (FAMU: Florida A&M University)H-Index: 11
Last. Hong Xiao (FAMU: Florida A&M University)H-Index: 10
view all 3 authors...
Background The use of Multi-Criteria Decision Analysis (MCDA) in health care has become common. However, the literature lacks systematic review trend analysis on the application of MCDA in health care. Aim To systematically identify applications of MCDA to the areas of health care, and to report on publication trends.
54 CitationsSource
#1Norman Daniels (Harvard University)H-Index: 44
#2Thalia Porteny (Harvard University)H-Index: 3
Last. Julian Urritia (Harvard University)H-Index: 1
view all 3 authors...
All societies face the need to make judgments about what interventions (both public health and personal medical) to provide to their populations under reasonable resource constraints. Their decisions should be informed by good evidence and arguments from health technology assessment (HTA). But if HTA restricts itself to evaluations of safety, efficacy, and cost-effectiveness, it risks being viewed as insufficient to guide health decision-makers; if it addresses other issues, such as budget impac...
32 CitationsSource
#1Dimitra Panteli (Technical University of Berlin)H-Index: 12
#2Helene Eckhardt (Technical University of Berlin)H-Index: 3
Last. Michael KuligH-Index: 2
view all 5 authors...
Background Coverage decisions determining the benefit baskets of health systems have been increasingly relying on evidence regarding patient benefit and costs. Relevant structures, methodologies, and processes have especially been established for pharmaceuticals but approaches differ. The objective of this work was thus to identify institutions in a broad range of European countries (n = 36) in charge of determining the value of pharmaceuticals for pricing and reimbursement purposes and to map t...
15 CitationsSource
#1Philip Wahlster (FAU: University of Erlangen-Nuremberg)H-Index: 11
#2Mireille Goetghebeur (Analytica)H-Index: 4
Last. Peter Kotanko (FAU: University of Erlangen-Nuremberg)H-Index: 39
view all 5 authors...
Background The diffusion of health technologies from translational research to reimbursement depends on several factors included the results of health economic analysis. Recent research identified several flaws in health economic concepts. Additionally, the heterogeneous viewpoints of participating stakeholders are rarely systematically addressed in current decision-making. Multi-criteria Decision Analysis (MCDA) provides an opportunity to tackle these issues. The objective of this study was to ...
28 CitationsSource
Cited By8
Newest
Source
#1Ibrahim Alabbadi (UJ: University of Jordan)H-Index: 5
view all 3 authors...
Abstract Background Access to healthcare services including innovative treatments is one of the most important objectives of healthcare system in Jordan. This research summarized one of the actual practices pertaining to health priority setting in Jordan with official requirement to use cost-effectiveness analysis. Objectives To address the role of economic evidence to inform the decisions and rationales drawn by health policy experts to optimize resources mobilization for new cancer drugs. Meth...
Source
Background Evidence-informed deliberative processes (EDPs) were recently introduced to guide health technology assessment (HTA) agencies to improve their processes towards more legitimate decision-making. The EDP framework provides guidance that covers the HTA process, ie, contextual factors, installation of an appraisal committee, selecting health technologies and criteria, assessment, appraisal, and communication and appeal. The aims of this study were to identify the level of use of EDPs by H...
Source
Abstract Technological innovation creates new treatment opportunities, while also putting healthcare budgets under strain. To deal with the rising costs of hospital medicines, the regional governments in Denmark have developed a new model for prioritising the adoption and use of hospital medicine. Marking a shift from previous policies, the new model formalises the evaluation of clinical benefit, adds an assessment of treatment costs and ensures a relatively high degree of direct stakeholder inv...
Source
#1Monika Wagner (Analytica)H-Index: 18
#2D Samaha (Analytica)H-Index: 2
Last. Michele TringaliH-Index: 3
view all 12 authors...
Source
#1Magdalena BujarH-Index: 3
#2Neil McAuslaneH-Index: 11
Last. Sam Salek (Cardiff University)H-Index: 17
view all 4 authors...
Background:To evaluate the quality of the decision-making processes of pharmaceutical companies during medicines development for evidence generation to support reimbursement of new medicines and th...
Source
#1Laia MaynouH-Index: 6
#2John Cairns (University of Bergen)H-Index: 59
Abstract Background Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work on the reasons behind these differences has been scarce. The main objective of this paper is to make a methodological contribution to existing research, specifically by outlining the systematic process of analysis to address such questions and determining the factors that might lead to different drug reimbursement decisions, and to explore its application in the...
1 CitationsSource
#1Finn Børlum Kristensen (University of Southern Denmark)H-Index: 12
#2Don Husereau (U of O: University of Ottawa)H-Index: 20
Last. Allan Wailoo (University of Sheffield)H-Index: 30
view all 17 authors...
The systematic use of evidence to inform healthcare decisions, particularly health technology assessment (HTA), has gained increased recognition. HTA has become a standard policy tool for informing decision makers who must manage the entry and use of pharmaceuticals, medical devices, and other technologies (including complex interventions) within health systems, for example, through reimbursement and pricing. Despite increasing attention to HTA activities, there has been no attempt to comprehens...
5 CitationsSource
Source
Source